JP Morgan Chase
CANF

JP Morgan Chase’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

JP Morgan Chase’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23
Closed -$1.22K – 7551
2023
Q3 		$1.22K Buy
+23
New +$1.3K ﹤0.01% 6618
2023
Q2 		– Sell
-5
Closed – – 6954
2023
Q1 		$0 Buy
+5
New +$359 ﹤0.01% 6724

Other funds holding CANF

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
SHIM
Stone House Investment Management Tunkhannock, Pennsylvania $558M AUM 14.72% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

JP Morgan Chase's CANF Position: Q4 2023 in Review

JP Morgan Chase sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2023, closing a stake of 23 shares — an estimated $1.22K sold.

JP Morgan Chase first reported a position in CANF in Q1 2023 and held it in 2 quarters. The position peaked at $1.22K in Q3 2023. 9 funds tracked by Wall St. Rank hold CANF as of Q4 2023.

  • JP Morgan Chase reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 23 Can-Fite BioPharma American Depositary Shares shares in Q4 2023, an estimated $1.22K.
  • JP Morgan Chase first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2023 and held it in 2 quarters.
  • JP Morgan Chase's Can-Fite BioPharma American Depositary Shares position peaked at $1.22K in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.